Designing Hybrid Onconase Nanocarriers for Mesothelioma Therapy: A Taguchi Orthogonal Array and Multivariate Component Driven Analysis

Abstract

Onconase (ONC) is a member of a ribonuclease superfamily that has cytostatic activity against malignant mesothelioma (MM). The objective of this investigation was to develop bovine serum albumin (BSA)-chitosan based hybrid nanoformulations for the efficient delivery of ONC to MM while minimizing the exposure to normal tissues. Taguchi orthogonal array L9 type design was used to formulate ONC loaded BSA nanocarriers (ONC-ANC) with a mean particle size of 15.78 ± 0.24 nm (ζ = -21.89 ± 0.11 mV). The ONC-ANC surface was hybridized using varying chitosan concentrations ranging between 0.100 and 0.175% w/v to form various ONC loaded hybrid nanocarriers (ONC-HNC). The obtained data set was analyzed by principal component analysis (PCA) and principal component regressions (PCR) to decode the effects of investigated design variables. PCA showed positive correlations between investigated design variables like BSA, ethanol dilution, and total ethanol with particle size and entrapment efficiency (EE) of formulated nanocarriers. PCR showed that the particle size depends on BSA, ethanol dilution, and total ethanol content, while EE was only influenced by BSA content. Further analysis of chitosan and TPP effects used for coating of ONC-ANC by PCR confirmed their positive impacts on the particle size, zeta potential, and prolongation of ONC release compared to uncoated ONC-ANC. PCR analysis of preliminary stability studies showed increase in the particle size and zeta potential at lower pH. However, particle size, zeta potential, and EE of developed HNC were below 63 nm, 31 mV, and 96%, respectively, indicating their stability under subjected buffer conditions. Out of the developed formulations, HNC showed enhanced inhibition of cell viability with lower IC50 against human MM-REN cells compared to ONC and ONC-ANC. This might be attributed to the better cell uptake of HNC, which was confirmed in the cell uptake fluorescence studies. These studies indicated that a developed nanotherapeutic approach might aid in reducing the therapeutic dose of ONC, minimizing adverse effects by limiting the exposure of ONC to normal tissues, and help in the development of new therapeutic forms and routes of administration.

Development of Metronidazole Loaded Chitosan Nanoparticles Using QbD Approach—A Novel and Potential Antibacterial Formulation

“…It is a biodegradable polymer and exhibits minimum toxicity, which make it an ideal carrier for the delivery of several drugs [ 15 ]. It has been widely used as one of the components in the formulation of novel carrier systems such as NPs [ 16 , 17 , 18 ], microspheres [ 19 ], and microcapsules [ 20 ] in the treatment of various illnesses, including infections [ 21 ] and cancers [ 15 ]. After oral delivery, CH remains intact in both the stomach and the small intestine.…”

Ribonucleases and Immunoribonucleases as Potential Modalities of Anticancer Therapy

“…To avoid it, the conjugations increasing the molecular size were performed. As a result of fusion onconase with albumin-chitosan polymer (hybrid nanocarrier) cationic molecule (named ONC-HNC) was created and tested in vitro with the human mesothelioma REN cells [78]. In comparison to onconase, ONC-HNC was more effectively delivered to cancer cells and significantly increased inhibition of cell viability.…”

Aerosol Delivery of siRNA to the Lungs. Part 2: Nanocarrier-based Delivery Systems

“…The natural polymers that have commonly been used for preparation of polymeric nanoparticles are albumin, chitosan, dextran, gelatin, lectins, and sodium alginate (Tekade R.K. and Chougule M.B., 2013, Tekade R.K. et al, 2014, Youngren S.R. et al, 2013).…”